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Central corneal thickness (CCT) is a highly heritable trait associated with complex eye
diseases such as keratoconus and glaucoma. We perform a genome-wide association meta-
analysis of CCT and identify 19 novel regions. In addition to adding support for known
connective tissue-related pathways, pathway analyses uncover previously unreported gene
sets. Remarkably, >20% of the CCT-loci are near or within Mendelian disorder genes. These
included FBN1, ADAMTS2 and TGFB2 which associate with connective tissue disorders
(Marfan, Ehlers-Danlos and Loeys-Dietz syndromes), and the LUM-DCN-KERA gene complex
involved in myopia, corneal dystrophies and cornea plana. Using index CCT-increasing var-
iants, we ﬁnd a signiﬁcant inverse correlation in effect sizes between CCT and keratoconus
(r=−0.62, P= 5.30 × 10−5) but not between CCT and primary open-angle glaucoma
(r=−0.17, P= 0.2). Our ﬁndings provide evidence for shared genetic inﬂuences between
CCT and keratoconus, and implicate candidate genes acting in collagen and extracellular
matrix regulation.
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Central corneal thickness (CCT) is a highly heritablequantitative trait, with heritability estimates rangingbetween 0.68 and 0.951–4. The corneal stroma, which
accounts for 90% of the corneal thickness in humans, is com-
posed of uniformly arranged type I collagen ﬁbrils that are critical
to the optical properties of the cornea. Corneal thinning is a
common feature of rare Mendelian connective tissue disorders,
such as Ehlers-Danlos syndrome (EDS), Marfan syndrome and
osteogenesis imperfecta (OI), and extreme thinning is a clinical
characteristic of brittle cornea syndrome (previously classiﬁed as
EDS type VIB based on non-ocular features shared with EDS)5–7.
Thinner CCT is also observed in more common ocular disorders
such as keratoconus8, and has been associated with development
and progression of primary open-angle glaucoma (POAG)9–12.
Keratoconus is the leading cause of corneal transplants world-
wide13 and its prevalence varies widely depending on the ethni-
city, ranging from 0.02 in 100,000 to 229 in 100,00014,15. POAG
accounts for around 74% of all cases of glaucoma, which is the
most common cause of irreversible blindness worldwide16.
Genetic variants that affect the functions of genes responsible
for maintaining the structural integrity of cornea are strong
candidates for involvement in corneal thickness-associated dis-
eases. We previously reported that six CCT-associated single
nucleotide polymorphisms (SNPs) were also associated with
keratoconus (using N= 874 cases and 6085 controls), including
two strong associations (mean odds ratio and lower 95% con-
ﬁdence interval estimates greater than 1.2), at the FOXO1 and
FNDC3B loci17. The latter was also shown to be associated with
POAG (using N= 2979 cases and 7399 controls), although not in
the direction that was expected (i.e., the CCT-decreasing allele
was associated with decreased risk of POAG)17.
Over 26 loci have been associated with CCT to date, explaining
around 8% of the CCT heritability17. Increased knowledge of the
genetic basis of the variation in CCT in the general population
promises to help in prioritising future research in corneal disease.
To identify new CCT-associated loci, we performed a larger
cross-ancestry genome-wide association study (GWAS) including
over 25,000 individuals of European and Asian descent, with
genotypes imputed to the 1000 genomes reference panel. Further,
we assess the relevance of CCT inﬂuencing loci to the risk of
keratoconus and POAG using slightly larger (keratoconus) and
substantially larger (POAG) ocular disease datasets than those
previously described17.
Results
Meta-analysis of GWAS studies. The overall study design and
main ﬁndings are depicted in Supplementary Fig. 1. In stage 1, we
meta-analysed GWAS results from 14 studies comprising 17,803
individuals of European ancestry (see details in Supplementary
Table 1). The inﬂation factor for European-speciﬁc meta-analysis
was 1.075 (lambda scaled to n= 1000 is 1.004), which suggests
the population stratiﬁcation had a negligible effect on our meta-
analysis. The European-speciﬁc meta-analysis identiﬁed 28
genome-wide signiﬁcant CCT loci (P < 5 × 10−8) (Supplementary
Table 2 and Supplementary Fig. 2a, b). Of these, seven were novel
loci and map (as per closest gene) to LTBP1, STAG1, ARL4C,
NDUFAF6, ADAMTS8, DCN and POLR2A. In stage 2, we
examined the 28 lead SNPs from stage 1 in the Asian-speciﬁc
meta-analysis (n= 8107) and found that 16, including the novel
lead SNPs within or close to ADAMTS8 and DCN, were sig-
niﬁcant after Bonferroni correction (P ≤ 1.79 × 10−3, 0.05/28),
further three other SNPs including the two novel close to STAG1
and NDUFAF6 were nominally signiﬁcant (P < 0.05). The effect
estimates of these 19 (16+ 3) loci were in the same direction and
order of magnitude as in the European-speciﬁc meta-analysis
(Tables 1 and 2 and Supplementary Table 2). Lead SNPs at four
of the nine remaining loci, including at LTBP1, did not meet our
ﬁltering criteria in the Asian-speciﬁc meta-analysis (see Methods
section). Lead SNPs at the remaining ﬁve loci showed the same
direction but did not reach nominal signiﬁcance, with SNPs at
ARL4C and POLR2A displaying little effect in Asian populations.
Meta-analysis of Asian-speciﬁc cohorts alone did not result in
novel genome-wide signiﬁcant ﬁndings (Supplementary Table 3
and Supplementary Fig. 3a, b). Because most loci had consistent
effect directions in both European and Asian meta-analyses, we
performed in stage 3 a cross-ancestry ﬁxed-effect meta-analysis to
detect additional loci associated with CCT (N= 25,910).
This stage 3 meta-analysis identiﬁed 44 loci associated with CCT
of which 19 were novel ﬁndings (Fig. 1 and Supplementary
Table 1 Results from cross-ancestry meta-analysis (chromosomes 1–7)
SNP Chr:bp Nearest gene A1/A2 European-speciﬁc meta-analysis Asian-speciﬁc meta-analysis Cross-ancestry meta-analysis
A1F β (SE) P A1F β (SE) P A1F β (SE) P N
rs96067 1:36571920 COL8A2 a/g 0.81 0.99 (0.48) 4.08E-02 0.56 3.94 (0.52) 3.48E-14 0.69 2.37 (0.35) 2.52E-11 25,910
rs4846476 1:218526228 TGFB2 c/g 0.23 −1.83 (0.46) 7.22E-05 0.31 −2.11 (0.56) 1.64E-04 0.26 −1.94 (0.35) 4.77E-08 23,830
rs115781177 2:33348494 LTBP1 a/g 0.93 −5.04 (0.89) 1.69E-08 NA NA (NA) NA 0.93 −5.04 (0.89) 1.69E-08 12,119
rs121908120 2:219755011 WNT10A a/t 0.03 −11.48 (1.58) 5.02E-13 NA NA (NA) NA 0.03 −11.48 (1.58) 5.02E-13 12,119
rs4608502 2:228134155 COL4A3 t/c 0.35 −2.47 (0.39) 4.68E-10 0.36 −2.19 (0.54) 5.12E-05 0.35 −2.37 (0.32) 1.18E-13 25,910
3:136138073 3:136138073 STAG1 d/r 0.24 −2.64 (0.47) 2.49E-08 0.19 −2.80 (1.09) 1.05E-02 0.23 −2.67 (0.43) 8.66E-10 20,982
rs9822953 3:156472071 TIPARPa t/c 0.67 2.69 (0.40) 2.57E-11 0.67 1.11 (0.61) 7.15E-02 0.67 2.22 (0.33) 5.13E-11 25,910
rs6445046 3:171933252 FNDC3B t/g 0.78 3.73 (0.49) 7.22E-14 0.66 3.17 (0.57) 3.59E-08 0.73 3.49 (0.37) 1.98E-20 24,899
3:177306757 3:177306757 TBL1XR1b d/r 0.39 −2.40 (0.42) 1.43E-08 0.53 −1.84 (0.52) 4.35E-04 0.44 −2.18 (0.32) 3.54E-11 23,060
rs28789690 4:149077899 NR3C2 a/g 0.07 −3.02 (0.74) 4.93E-05 0.11 −3.49 (0.84) 3.59E-05 0.09 −3.22 (0.55) 7.60E-09 25,128
rs10471310 5:64548961 ADAMTS6 t/c 0.37 2.62 (0.39) 1.74E-11 0.39 1.87 (0.53) 4.36E-04 0.38 2.36 (0.31) 6.12E-14 25,910
rs249767 5:141918585 FGF1 t/c 0.78 2.01 (0.46) 1.56E-05 0.51 2.15 (0.54) 7.30E-05 0.67 2.07 (0.35) 4.60E-09 25,910
rs35028368 5:178671146 ADAMTS2 i/r 0.29 −2.34 (0.48) 1.25E-06 0.11 −2.59 (0.99) 8.80E-03 0.26 −2.39 (0.43) 3.69E-08 23,060
rs13191376 6:45522139 RUNX2 t/c 0.35 −2.07 (0.39) 1.78E-07 0.14 −1.99 (0.91) 2.94E-02 0.32 −2.06 (0.36) 1.55E-08 25,910
rs1412710 6:75837203 COL12A1 t/c 0.15 −2.56 (0.56) 5.26E-06 0.33 −1.93 (0.58) 9.19E-04 0.24 −2.26 (0.40) 2.42E-08 24,899
rs1931656 6:82610188 FAM46A a/t 0.45 2.17 (0.39) 2.75E-08 0.47 2.96 (0.52) 2.13E-08 0.46 2.451 (0.31) 6.32E-15 24,899
6:169553553 6:169553553 THBS2 i/r 0.19 −2.98 (0.62) 1.76E-06 0.30 −2.22 (0.69) 1.41E-03 0.24 −2.64 (0.46) 1.27E-08 23,060
7:66262284 7:66262284 RABGEF1c d/r 0.27 −3.32 (0.44) 1.25E-13 0.34 −2.73 (0.56) 1.03E-06 0.29 −3.09 (0.35) 9.62E-19 24,071
rs2106166 7:92668332 SAMD9 a/t 0.57 1.95 (0.40) 1.39E-06 0.38 1.48 (0.55) 7.99E-03 0.50 1.79 (0.32) 4.63E-08 24,899
Nearest gene (reference NCBI build37) is given as locus label, but this should not be interpreted as providing support that the nearest gene is the best candidate, a list including all the genes +/− 200 kb
of the lead SNP is presented in Supplementary Table 12
New loci are in bold
SNP rsID, Chr:bp chromosome: base pair, A1 risk allele, A2 other allele, A1F frequency of allele A1, β effect size on CCT based on allele A1, SE standard error of the effect size, i insertion, d deletion,
r reference, N number of individuals included in the meta-analysis per variant
aThe lead SNP is located in a validated non-coding mRNA, LINC00886
bThe lead SNP is located in a validated non-coding mRNA, LINC00578
cIn Lu et al.17 this locus was reported as two loci (VKORC1L1 and C7orf42)
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Figs. 4, 5). These 19 loci included ﬁve of the seven loci found in
stage 1 (European-meta-analysis) and 14 novel ones with similar
effect size and direction across-ancestries, see Tables 1 and 2. Two
of the 44 loci are driven by low-frequency variants (i.e., 0.01 <
minor allele frequency [MAF] < 0.05) identiﬁed in the European-
speciﬁc meta-analysis (both are monomorphic in Asians), one
novel in LTBP1 and one known in WNT10A18. The remaining 42
loci were all consistent across ancestries.
Independent signals. In our previous CCT GWAS we identiﬁed
loci harbouring multiple independent variants17. To identify
additional independently associated variants in European popu-
lation, we performed conditional and joint multiple-SNP (CoJo)
analysis implemented in the program GCTA. We used genotype
data of 2582 unrelated Australians from the BMES cohort19. The
CoJo analysis resulted in 16 independent SNPs, of which seven
have not been previously associated with CCT (Table 3). Thus, in
total, we identiﬁed 44 loci associated with CCT, harbouring 54
independent association signals (i.e., 28 previously published+ 19
from the cross-ancestry meta-analysis+ 7 from CoJo analyses).
Gene-based association analysis. To further identify loci not
implicated in the single marker association tests, we performed
gene-based tests using the software VEGAS220 using a ‘−10 kb’
window (see Methods section). We performed separate analyses
for European-speciﬁc and Asian-speciﬁc meta-analyses results.
In total 24,769 autosomal genes were analysed. Hence, we
set our Bonferroni-corrected gene-based signiﬁcant threshold as
Pgene-based < 2.02 × 10−6 (0.05/24,769). In addition to genes
implicated through the single marker association tests, we found
signiﬁcant association of the CDO1 gene with CCT (Pgene-based=
3.74 × 10−7, Supplementary Data 1). This gene showed strong
association in the European gene-based study (Pgene-based=
2.00 × 10−7), with a top variant rs34869 (P= 7.88 × 10−8) driving
the association.
Clinical relevance of CCT-associated loci. We ﬁrst investigated
whether the CCT-associated variants inﬂuence susceptibility to
keratoconus and to POAG. Since keratoconus is characterized by
progressive thinning of the cornea and reduced CCT is associated
with POAG, we expected—if the underlying mechanisms are
shared—that the CCT-reducing alleles would also increase the
risks of keratoconus and of POAG. We aimed to test the asso-
ciation of all 54 independent CCT SNPs (or their proxies, r2 > 0.8)
in the case-control studies. However, after quality control, only 36
SNPs were available in the keratoconus studies; all 54 SNPs were
available in the POAG studies. We used a P-value of 5.56 × 10−4
(0.05/90) as Bonferroni-corrected signiﬁcance threshold.
The keratoconus cohorts comprised 933 cases and 5946
controls of European ancestry. Overall, we found a signiﬁcant
negative correlation of effect sizes across CCT and keratoconus
(r=−0.62, P= 5.30 × 10−5) (Fig. 2a, Supplementary Table 4),
this correlation was largely unchanged if the known SNPs in
ZNF469, FOXO1, COL5A1 and MPDZ/NFIB were removed from
the analysis (r=−0.61, P= 2.04 × 10−4). Of the 36 CCT SNPs
tested for association with disease risk in the keratoconus studies,
three were signiﬁcant and with the expected direction of effect
(rs66720556 between MPDZ-NFIB, rs3132303 between RXRA-
COL5A1, and rs2755238 close to FOXO1). Another 14 indepen-
dent SNPs were associated at a nominal level of signiﬁcance (P <
0.05). Of these, 12 showed the expected risk effect direction,
including three tagging known CCT loci that had not reached
nominal signiﬁcance in our previous study (using a different
proxy SNP), and four tagging novel CCT loci (DCN, LTBP1,
STAG1, and THBS2). Of those, rs7308752 in DCN displayed the
smallest P-value (P= 6.33 × 10−3, Supplementary Table 4).
Analyses in POAG cohorts included 5008 cases and 35,472
controls of European ancestry. None of the 54 available CCT-
SNPs were signiﬁcantly associated with POAG after correcting for
multiple testing (Supplementary Table 5). Further, no correlation
in effect sizes between CCT and POAG was found (r=−0.17,
P= 0.2, Fig. 2b). Five variants were nominally associated
(rs6445046 in FNDC3B, rs66720556 between MPDZ and NFIB,
Table 2 Results from cross-ancestry meta-analysis (chromosomes 8–22)
SNP Chr:bp Nearest gene A1/A2 European-speciﬁc meta-analysis Asian-speciﬁc meta-analysis Cross-ancestry meta-analysis
A1F β (SE) P A1F β (SE) P A1F β (SE) P N
rs3808520 8:23164773 LOXL2 c/g 0.21 2.50 (0.48) 2.61E-07 0.10 2.02 (0.88) 2.28E-02 0.18 2.39 (0.42) 2.02E-08 24,899
rs10429294 8:95969322 NDUFAF6 t/c 0.50 2.36 (0.39) 2.21E-09 0.66 1.34 (0.55) 1.60E-02 0.56 2.02 (0.32) 3.48E-10 24,899
rs7026684 9:4215308 GLIS3 a/g 0.36 −2.00 (0.39) 4.24E-07 0.39 −1.81 (0.55) 1.04E-03 0.37 −1.94 (0.32) 1.73E-09 25,910
rs66720556 9:13559717 MPDZ a/t 0.18 −1.86 (0.51) 3.01E-04 0.25 −3.80 (0.59) 2.18E-10 0.21 −2.68 (0.39) 6.06E-12 24,071
rs10980623 9:113660537 LPAR1 a/g 0.79 −2.63 (0.46) 1.06E-08 0.79 −3.43 (0.63) 6.06E-08 0.79 −2.90 (0.37) 5.63E-15 25,910
rs3132303 9:137444298 COL5A1 c/g 0.26 5.23 (0.49) 6.11E-26 0.26 5.91 (0.71) 1.21E-16 0.26 5.45 (0.40) 8.35E-41 24,899
rs7040970 9:139859013 LCN12 t/c 0.49 3.35 (0.41) 3.54E-16 0.72 1.80 (0.63) 4.31E-03 0.56 2.89 (0.34) 4.75E-17 24,899
rs35809595 10:63831928 ARID5B a/g 0.40 −2.29 (0.39) 8.97E-09 0.36 −2.66 (0.53) 6.56E-07 0.39 −2.43 (0.32) 3.40E-14 24,899
rs2419835 10:115296564 HABP2 t/c 0.86 2.21 (0.54) 4.70E-05 0.45 2.33 (0.52) 9.01E-06 0.65 2.27 (0.37) 1.74E-09 25,910
rs4938174 11:110913240 ARHGAP20-C11orf53 a/g 0.30 1.82 (0.41) 9.97E-06 0.15 3.74 (0.75) 6.14E-07 0.26 2.26 (0.36) 3.59E-10 25,910
rs56009602 11:130289612 ADAMTS8 t/c 0.05 6.86 (0.92) 1.30E-13 0.10 7.24 (0.93) 1.25E-14 0.08 7.05 (0.66) 1.16E-26 25,910
rs7308752 12:91527181 DCN a/g 0.91 3.87 (0.67) 1.07E-08 0.73 2.28 (0.68) 7.91E-04 0.82 3.08 (0.48) 1.34E-10 25,302
rs11553764 12:104415244 GLT8D2 t/c 0.17 3.19 (0.53) 2.77E-09 0.20 4.14 (0.67) 8.62E-10 0.18 3.55 (0.42) 2.47E-17 24,899
rs10161679 13:23243645 FGF9-SGCGa a/g 0.71 −2.40 (0.45) 1.41E-07 0.72 −1.99 (0.64) 2.16E-03 0.71 −2.26 (0.37) 1.28E-09 24,899
13:41112152 13:41112152 FOXO1 i/r 0.10 −5.44 (0.66) 2.15E-16 0.03 −2.52 (1.81) 1.64E-01 0.10 −5.10 (0.62) 2.54E-16 24,071
rs56223983 14:81814754 STON2 t/g 0.30 2.01 (0.42) 1.83E-06 0.30 1.99 (0.58) 5.94E-04 0.30 2.00 (0.34) 4.14E-09 25,910
rs785422 15:30173885 TJP1 t/c 0.11 −4.01 (0.63) 2.65E-10 0.08 −3.50 (1.26) 5.75E-03 0.10 −3.91 (0.56) 5.72E-12 21,810
rs8030753 15:48801935 FBN1 t/c 0.13 2.02 (0.55) 2.75E-04 0.27 2.51 (0.59) 2.29E-05 0.20 2.25 (0.40) 2.87E-08 25,910
rs12912010 15:67467143 SMAD3 t/g 0.22 2.76 (0.47) 6.40E-09 0.36 2.21 (0.53) 3.92E-05 0.28 2.52 (0.35) 1.50E-12 24,899
rs4843040 15:85838636 AKAP13b t/c 0.24 −2.92 (0.44) 3.62E-11 0.47 −2.35 (0.52) 6.68E-06 0.33 −2.68 (0.33) 1.68E-15 25,910
rs930847 15:101558562 LRRK1 t/g 0.77 −3.57 (0.45) 3.19E-15 0.73 −3.79 (0.61) 7.82E-10 0.76 −3.64 (0.36) 1.63E-23 25,910
rs35193497 16:88324821 ZNF469 t/g 0.36 −6.23 (0.43) 8.64E-47 0.29 −4.92 (0.62) 2.34E-15 0.34 −5.80 (0.35) 8.08E-60 24,899
rs4792535 17:14565130 HS3ST3B1 t/c 0.29 −2.43 (0.41) 3.61E-09 0.47 −2.04 (0.54) 1.72E-04 0.36 −2.29 (0.32) 3.13E-12 25,302
rs8133436 21:47519535 COL6A2 t/c 0.05 3.90 (1.07) 2.84E-04 0.25 3.47 (0.72) 1.85E-06 0.18 3.61 (0.60) 2.17E-09 24,899
rs71313931 22:19960184 ARVCF c/g 0.71 −2.23 (0.44) 5.49E-07 0.78 −2.22 (0.70) 1.59E-03 0.73 −2.23 (0.37) 3.21E-09 24,071
Nearest gene (reference NCBI build37) is given as locus label, but this should not be interpreted as providing support that the nearest gene is the best candidate, a list including all the genes +/− 200 kb
of the lead SNP is presented in Supplementary Table 12
New loci are in bold
SNP rsID, Chr:bp chromosome: base pair, A1 risk allele, A2 other allele, A1F frequency of allele A1, β effect size on CCT based on allele A1, SE standard error of the effect size, i insertion, d deletion,
r reference, N number of individuals included in the meta-analysis per variant
aThe lead SNP is located 228KB 3′ of the pseudogene BASP1P1
bThe lead SNP is located in pseudogene ADAMTS7P4
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rs56009602 in ADAMTS8, rs10161679 between SNORD36 and
BASP1P1, and rs2755238 close to FOXO1). Of these, association
between rs6445046 in FNDC3B and POAG was the strongest
(P= 3.18 × 10−3). However, as in our previous study17, the CCT-
decreasing allele tagging FNDC3B was associated with a decreased
risk of glaucoma rather than the expected increased risk. The next
strongest association was for rs2755237 close to FOXO1 (P=
3.70 × 10−3); in this instance with the CCT-decreasing allele C
being associated with an increased risk of glaucoma (rs2755237-C
allele glaucoma OR= 1.15).
We then investigated whether CCT-associated loci are located
in the vicinity (less than 1Mb away) of rare Mendelian disorder
genes (Supplementary Data 2). We identiﬁed that 20.5% (9/44) of
the CCT loci are within 1Mb of a Mendelian gene implicated in
rare corneal or connective tissue diseases. In addition to the more
immediate connections previously recognised (COL5A1—classi-
cal EDS, ZNF469—brittle cornea syndrome, COL8A2—Fuchs
endothelial dystrophy), AGBL1—a Fuchs endothelial dystrophy
gene21—is 784 kb away from rs4843040 on chr15q25.3, and
SMAD3 is a Loeys-Dietz connective tissue syndrome gene. For
the CCT loci identiﬁed here, DCN (12 kb from rs7308752) and
KERA in the same locus (75 kb from rs7308752), are involved in
congenital stromal corneal dystrophy (OMIM: 610048) and
Cornea plana 2 (OMIM:217300), respectively. Finally, three
connective tissues disease genes harboured lead SNPs for new
CCT loci, ADAMTS2 (intronic lead SNP rs35028368) involved in
EDS, type VIIC (OMIM: 225410), FBN1 (intronic lead SNP
rs8030753) the Marfan syndrome major gene (OMIM: 154700),
and TGFB2 (intronic lead SNP rs4846476) a Loeys-Dietz
syndrome gene.
Regulatory potential of CCT-associated variants. We explored
regulatory annotations within the 54 independent CCT lead SNPs
and their proxies (r2 > 0.8) using different tools (see Methods
section). In total, 974 variants (i.e., 54 lead SNPs+ 920 SNPs in
LD) were examined. Of these, 118 were prioritized including the
54 lead SNPs and another 64 SNPs which were selected based on
their RegulomeDB score22 (i.e.,1a–1f, 2a–2c or 3a). SNPs with a
score from 1a–1f to 2a–2c were classiﬁed as showing maximum
evidence for being located in regulatory regions, while SNPs with
a score of 3a were classiﬁed as showing medium evidence (Sup-
plementary Data 3). In total, 63% (75/118) of the prioritized SNPs
overlap with at least two regulatory elements of the ENCODE
data (i.e., promoter or enhancer histone marks, DNase I hyper-
sensitive sites, transcription factor or other protein-binding sites
and eQTLs). Strong enrichment for histone modiﬁcations, par-
ticularly, H4K20me1 (which indicates transcriptional activation),
was also found when results from the European-speciﬁc meta-
analysis were assessed using GARFIELD (http://www.ebi.ac.uk/
birney-srv/GARFIELD) (Supplementary Fig. 6). Additionally, we
found 26 SNPs in eight loci showing a cis-eQTL effect in skin,
which share the same embryonic origin as the cornea (Supple-
mentary Data 3). Further, we tested if genes in associated CCT
loci were highly expressed in any of the 209 Medical Subject
Heading (MeSH) annotations used in DEPICT23. Tissue-
enrichment analyses showed 33 FDR-associated (<0.05) tissues
or cell type annotations. Of these, one annotation included the
musculoskeletal system, ﬁve included tissues such as the muscle
and connective tissue, and nine included cell types such as
myocytes, osteoblast, chondrocytes, mesenchymal stem cells,
stromal cells and ﬁbroblasts (Supplementary Table 6). DEPICT
prioritized 54 genes, of which 85% (46/54) are expressed in the
human cornea. High expression levels (>200 PLIER) were
observed for SMAD3, COL12A1 and DCN, LUM, KERA (Sup-
plementary Table 7), the latter three being at the same “DCN”
locus.
Pathway analysis. We tested enrichment of the genes deﬁned by
VEGAS2 in 9981 pathways or gene-sets derived from the Biosys-
tem’s database. Using a 10 kb window in the VEGAS2 computa-
tion, we identiﬁed 23 pathways that were signiﬁcantly enriched
after correcting for multiple testing (Pgene-set < 5.01 × 10−6),
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Fig. 1 Manhattan plot of CCT in the cross-ancestry meta-analysis. Manhattan plot of the GWAS meta-analysis for CCT in the cross-ancestry analysis
(n= 25,910). The plot shows −log10-transformed P-values for all SNPs. The red horizontal line represents the genome-wide signiﬁcance threshold of P <
5.0 × 10−8; the blue horizontal line indicates a P-value of 1 × 10−5. Loci are annotated to the nearest gene as in Tables 1 and 2. New loci are in bold
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Supplementary Data 4. The majority of these gene-sets are
involved in the metabolic activities associated with collagen and
extracellular matrix (ECM). We conﬁrmed the previously identi-
ﬁed signiﬁcant association of the collagen trimer pathway
(GO:0005581) with CCT17. Additional pathways involved in
basement membrane (GO:0005604), TGF-β regulation
(GO:0071636) and skeletal system development (GO:0001501),
were also identiﬁed as associated with CCT. Similar pathways were
observed using single variants with sub-threshold association P-
values < 1 × 10−4 as input for the interval enrichment analysis
(INRICH) method, Supplementary Table 8. Pathway analysis using
a 200 kb window in VEGAS2, showed comparable pathways and
additionally revealed the endoplasmic-reticulum-associated protein
degradation (ERAD) pathway (GO:0036503) (Supplementary
Data 5). The ERAD pathway also emerged as an overrepresented
canonical pathway in the Ingenuity Pathway Analysis (IPA)
(Supplementary Fig. 7), along with pathways related to connective
tissue disorders and metabolism (Supplementary Tables 9, 10).
The FUMA platform (https://ctg.cncr.nl/software/fuma_gwas)
highlighted that eight of the closest genes to the 44 CCT cross
ethnic meta-analysis lead variants are amongst the 64 ﬁbroblastic
signature genes overexpressed in cancer cells that have undergone
epithelial to mesenchymal transition24: THBS2, COL5A1, FBN1,
LOXL2, DCN, LUM, COL6A2 and GLT8D2.
Discussion
In this study, we identiﬁed 44 loci associated with CCT (42 across
ancestry and two European speciﬁc—LTBP1 andWNT10A), 19 of
which are novel ﬁndings. We also found that six of the 44 loci
harbour multiple independent signals associated with CCT.
Furthermore, we explored the relevance of CCT to complex eye
diseases (i.e., keratoconus and POAG) and to Mendelian dis-
orders. We found evidence of a strong inverse correlation in effect
sizes between CCT and keratoconus, but not between CCT and
POAG. Interestingly, 20.5% (9/44) of the CCT-associated loci are
located close or within genes implicated in rare corneal or con-
nective tissue disorders.
We conﬁrmed all loci, except one (rs3749260 in GPR15),
reported in our previous study by Lu et al.17 The variant in
GPR15 found by Lu et al.17 in the European-speciﬁc analysis did
not reach genome-wide signiﬁcance in either our European-
speciﬁc (P= 2.15 × 10−6) or cross-ancestry meta-analysis (P=
6.93 × 10−5); this could be due to the additional samples analysed
or/and different quality of imputation. Additionally, in our study,
we identiﬁed only one signal in the chr7q11.21 region, which in
Lu et al.17 was reported as two independent loci, TMEM248 (also
called as C7orf42) and VKORC1L1. Interestingly, the variant
found in our study (rs34557764) lies in RABGEF1 with estab-
lished eQTL effect in 90 tissues, inﬂuencing the expression of
various genes including TMEM248 in testis, and VKORC1L1 in
skin, blood and esophagus muscularis25,26, and further studies
will be needed to ascertain the associated target gene(s). Overall,
we report 44 loci harbouring 54 independent CCT-associated
SNPs. These associations explain 8.5% and 7.2% of narrow sense
CCT heritability in the European and Asian populations,
respectively. Despite the small increase in the variance explained
in the present study (~0.2%), the new loci greatly improved our
understanding of potential underlying mechanisms.
At the newly identiﬁed CCT loci, if we select the nearest gene
to the top SNP, we can putatively identify genes related to col-
lagen and ECM (ADAMTS2, ADAMTS8, COL6A2, COL12A1,
FBN1, LOXL2, LUM/DCN/KERA, THSB2), skeletal morphogen-
esis (RUNX2), embryonic development and cell growth (FGF1),
TGF-β signalling (TGFB2, LTBP1), binding processes (ARVCF,
STAG), coagulation and ﬁbrinolysis systems (HABP2), endocytic
machinery (STON2) and mitochondrial processes (NDUFAF6). It
is important to stress that for several of these genes, the nearest
gene may not be the relevant gene because the associated SNPs
can have their primary effect on a more distant gene or genes.
However, for a subset of the above nearest genes, additional
information is available to support the noted gene. For example,
knockout mouse models available for these genes have shown a
variety of cornea-related phenotypes, including thin corneal
stroma (FBN1, KERA, LUM, TGFB2)27–32, corneal opacity
(LUM)30–32, absence of corneal endothelium (TGFB2)27, delayed
corneal endothelium maturation and increased thickness
(COL12A1)33. While in other mouse models, observed pheno-
types included fragile skin (ADAMTS2, DCN, LUM)30,31,34,35 or
bone abnormalities (RUNX2, COL12A1)33,36. Moreover,
Table 3 CCT-associated variants from the conditional and joint analysis of the meta-analysis of European studies and replication
in Asians
SNP Chr:bp Nearest gene Annotation Previously reported
SNP (ref)a
A1/
A2
Meta-analysis in Europeans CoJo analysis in Europeans Meta-analysis in Asians
A1F β (SE) P A1F β (SE) PCOJO LD_r A1F β (SE) P
rs1309531 5:64306311 CWC27 Intronic a/t 0.55 −2.4 (0.379) 2.439E-10 0.56 −2.096 (0.383) 4.28E-08 0.130 0.63 −1.184 (0.547) 3.03E-02
rs10064391 5:64686659 ADAMTS6 Intronic rs230712117 a/g 0.63 −2.765 (0.397) 3.182E-12 0.62 −2.484 (0.4) 5.53E-10 0.000 0.70 −0.889 (0.601) 1.39E-01
rs1931656 6:82610188 148 kb 5’ of
FAM46A
Intronic a/t 0.45 2.172 (0.391) 2.749E-08 0.45 2.383 (0.393) 1.31E-09 −0.104 0.47 2.965 (0.529) 2.13E-08
rs9361886 6:82778502 101 kb 3’ of
IBTK
Intergenic rs153813817 t/c 0.54 2.391 (0.445) 7.665E-08 0.56 2.637 (0.447) 3.66E-09 0.000 0.57 2.35 (0.66) 3.67E-04
rs3094339 9:136884738 VAV2-BRD3 Intergenic a/g 0.71 −2.804 (0.426) 4.682E-11 0.72 −3.042 (0.427) 1.01E-12 −0.008 0.53 0.671 (0.559) 2.30E-01
rs4841899 9:137424412 92 kb 3’ of
RXRA
Intergenic rs4842044,
rs153647866,67
t/c 0.67 −2.993 (0.405) 1.413E-13 0.67 −2.289 (0.416) 3.60E-08 −0.037 0.63 −2.383 (0.596) 6.32E-05
rs1536482 9:137440528 93 kb 5’ of
COL5A1
Intergenic rs3132306, rs3118516,
rs311852017,68
g/a 0.66 4.569 (0.399) 1.95E-30 0.66 3.455 (0.425) 4.60E-16 0.388 0.68 2.864 (0.601) 1.85E-06
rs3132303 9:137444298 89 kb 5’ of
COL5A1
Intergenic c/g 0.26 5.236 (0.497) 6.11E-26 0.26 3.55 (0.544) 6.86E-11 −0.039 0.26 5.912 (0.714) 1.21E-16
rs7032489 9:137559775 COL5A1 Intronic rs704452917 c/g 0.86 4.033 (0.547) 1.637E-13 0.86 4.296 (0.548) 4.64E-15 −0.008 0.81 1.845 (0.685) 7.08E-03
rs116878472 12:104210992 NT5DC3 Intronic t/c 0.97 −8.392 (1.506) 2.523E-08 0.97 −8.829 (1.509) 4.95E-09 −0.058 NA NA NA
rs11111869 12:104402485 GLT8D2 Intronic rs156489217 g/a 0.83 −3.174 (0.51) 4.77E-10 0.83 −3.308 (0.511) 9.40E-11 0.000 0.78 −3.479 (0.636) 4.38E-08
rs2034809 15:101555399 LRRK1 Intronic rs4965359 g/a 0.51 1.844 (0.4) 4.047E-06 0.51 2.545 (0.407) 3.82E-10 −0.177 0.34 2.161 (0.579) 1.88E-04
rs930847 15:101558562 LRRK1 Intronic rs93084717 g/t 0.23 3.573 (0.453) 3.194E-15 0.22 3.955 (0.461) 9.17E-18 −0.042 0.27 3.793 (0.617) 7.82E-10
rs752092 15:101781934 CHSY1 Intronic a/g 0.66 −2.205 (0.396) 2.554E-08 0.67 −2.19 (0.397) 3.46E-08 0.000 0.79 −1.745 (0.652) 7.40E-03
rs35193497 16:88324821 169 kb 5’ of
ZNF469
Intergenic rs654022317 t/g 0.36 −6.238 (0.434) 8.637E-47 0.34 −4.654 (0.495) 4.90E-21 0.653 0.29 −4.928 (0.622) 2.34E-15
rs28687756 16:88328928 165 kb 5’ of
ZNF469
Intergenic t/g 0.57 −7.507 (0.584) 8.418E-38 0.53 −4.566 (0.667) 7.84E-12 0.000 NA NA NA
Results from the conditional and joint analysis, genotype data from BMES cohort was used (N= 2582)
Nearest gene, (reference NCBI build37) is given as locus label, but this should not be interpreted as providing support that the nearest gene is the best candidate, a list including all the genes+/− 200 kb
of the lead SNP is presented in Supplementary Table 12
SNP rsID, Chr:bp chromosome: base pair, A1 risk allele, A2 other allele, A1F frequency of allele A1, β effect size on CCT based on allele A1, SE standard error of the effect size, i insertion, d deletion, r
reference, PCOJO = P-value after CoJo analyses
aSNPs in LD (r2 > 0.5) with SNP from CoJo analyses. In bold novel independent CCT-associated SNPs
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connections between ECM, skeletal and TGF-β signalling path-
ways give support for the implicated genes to inﬂuence CCT. For
instance, it has been reported that ﬁbrillin (encoded by FBN1)
plays an important role in the ECM by controlling TGF-β sig-
nalling37. In addition, the latent transforming growth factor
β–binding protein 1 (encoded by LTBP1) is an ECM protein
thought to mediate the binding between ﬁbrillins and TGF-β,
inﬂuencing the growth factors availability in bone and connective
tissues.
Another locus of interest harbouring genes related to ECM and
collagen is the “DCN” locus (top SNP rs7308752) in which DCN,
KERA and LUM genes are located. Decorin (encoded by DCN, the
closest gene to rs7308752) is a leucine-rich proteoglycan that
promotes the formation of collagen ﬁbers but also binds to the
various isoforms of TGF-β and ﬁbronectins38. Mutations in DCN
have been identiﬁed in congenital stromal corneal dystrophy35,39;
which produces characteristic corneal opacity and increased
corneal thickness35, making it an excellent candidate CCT gene.
However, rs7308752 also shows a signiﬁcant cis-eQTL effect
(P= 3.1 × 10−6, in adipose tissue), modifying the expression of
KERA, a keratan sulfate proteoglycan vital for maintaining cor-
neal transparency. Mutations in KERA cause cornea plana-2
(OMIM:217300)40,41, a recessive corneal disorder characterised
by ﬂattening of the normally convex corneal surface. Addition-
ally, LUM, another gene in the region (30 kb apart from
rs7308752), is a member of the small interstitial proteoglycan
gene family and has been implicated in high myopia32,42. In the
ocular tissue database43, all three genes showed high expression
levels in the cornea, with KERA showing the highest expression.
Our gene-based analysis identiﬁed association of the CDO1
gene with CCT. The CDO1 protein, is a cysteine dioxygenase type
1, involved in various metabolic pathways. Expression studies in
mouse found that CDO1 is overexpressed in cornea compared
with the lens; and based on its function, may play a role in
protection against oxidative stress44. The top variant, rs34869,
leading association of CDO1, is an established eQTL in trans-
formed ﬁbroblasts26, modifying the expression levels of CDO1
and it is encompassed within promoter histone marks and DNase
I hypersensitive sites in at least 20 tissues.
Corneal thinning is one of the clinical features of keratoconus.
We found in the keratoconus analysis a consistent direction of effect
in 77% (28/36) of the CCT-associated SNPs (Fig. 2a). This ﬁnding
suggests that the effect of variants on keratoconus is mediated
through their effect on CCT. We did not observe the same trend in
the POAG analyses (Fig. 2b), with our data providing no support
for a role for CCT SNPs in determining POAG risk.
Interestingly, besides the “DCN” locus, three other loci harbour
genes implicated in Mendelian diseases including rare connective
tissue, inﬂammatory and eye disorders with corneal thinning as
one of their clinical features, giving weight for them to be
prioritized in follow-up studies. The cross-ancestry GWAS
revealed an intronic variant (rs8030753) in the FBN1 gene.
Mutations in FBN1 are the major cause of Marfan syndrome, an
autosomal dominant disorder characterized by multiple mani-
festations in the ocular, skeletal, and cardiovascular systems.
Patients with Marfan syndrome have ﬂattened corneas with
reduced stromal thickness45. Common genetic variants in FBN1
have also been associated with ocular refraction46. The
rs8030753 shows a signiﬁcant cis-eQTL effect modifying the
expression of FBN1 in whole blood (P= 4.1 × 10−10)26. Fur-
thermore, we identiﬁed an intronic variant in ADAMTS2, which
encodes a metalloproteinase involved in collagen metabolism47;
Mutations in ADAMTS2 have been found in patients with EDS,
type VIIC48, a recessive inherited connective-tissue disorder. We
also identiﬁed a common CCT variant (rs4846476) in TGFB2. It
has been shown that TGFB2 is down-regulated in skin ﬁbroblasts
of brittle cornea syndrome patients carrying PRDM5 mutations49.
Our analysis brings the number of CCT-associated loci implicated
in Mendelian diseases to nine, representing 20.5% (9/44) of the
CCT loci. Most of the Mendelian disorders genes (8/9) are located
within a 200 kb window from the lead SNP (Supplementary
Table 12) with the exception of AGBL, located −784 kb away
from rs4843040 in the 15q25.3 CCT-locus. Studies correlating
gene variation to gene expression have found that most of the
enhancers are located within a 200 kb window50,51, supporting
the hypothesis that lead CCT–associated SNPs might have an
impact on the expression of genes that cause rare eye and con-
nective tissue disorders. Our study reveals a considerable pro-
portion of Mendelian genes as candidate genes involved in a
quantitative trait.
Although ﬁndings of pathway analyses remain speculative, our
exhaustive analyses suggest that the leading pathways implicated
in CCT are related to the function and metabolism of connective
tissue (e.g., collagen, ECM and basement membrane), as well as
the regulation of TGF-β signalling, the development of skeletal
system, and the ERAD pathway.
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Fig. 2 Correlation of effect sizes between CCT and keratoconus and CCT and primary-open angle glaucoma. Each dot represents a CCT-associated variant.
In green, variants that surpassed the Bonferroni-corrected signiﬁcance threshold (P < 5.56 × 10−4) in the keratoconus analysis (a). In blue, variants that
were associated with a nominal level of signiﬁcance (P < 0.05) in the keratoconus or primary-open angle glaucoma analysis. In gray, variants that did not
show association with keratoconus or primary-open angle glaucoma (P > 0.05). a shows correlation of effect sizes between CCT and keratoconus, b shows
correlation of effect sizes between CCT and primary-open angle glaucoma
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In conclusion, we have identiﬁed 19 novel loci associated with
CCT and novel independent signals in six known loci. Together,
CCT loci clearly point to genes implicated in collagen related
pathways and ECM metabolism. The enrichment analyses high-
lighted gene-sets involved in collagen ﬁbrils, ECM organisation,
TGF-β signalling and ﬁbroblastic determination, all ﬁtting with a
largely stromal contribution to CCT. Functional studies need to
be performed to conﬁrm which gene or genes are relevant at each
locus and to assess the underlying mechanisms by which genetic
variation inﬂuences CCT some of which promise to inform on
the risk of complex diseases such as keratoconus.
Methods
Study design and sample description. We performed meta-analyses of 1000
genomes phase 1 (integrated variant set- March 2012 release) imputed GWASs on
CCT and tested signiﬁcance of associations in keratoconus and POAG cohorts for
lead CCT SNPs. The overall study design and main ﬁndings are depicted in
Supplementary Fig. 1. In total, 19 CCT cohorts (N= 25,910) from the International
Glaucoma Genetics consortium (IGGC) participated in this study. In stage 1, we
performed a meta-analysis of cohorts of European ancestry (14 cohorts, N=
17,803). In stage 2, genome-wide signiﬁcant variants (P < 5 × 10−8) from stage 1
were tested in a meta-analysis of cohorts of Asian ancestry (5 cohorts, N= 8107).
We then performed in stage 3, a joint meta-analysis of European-speciﬁc and
Asian-speciﬁc results. The individual cohorts are as described in detail in previous
publications18,52, with summary statistics and imputation details in Supplementary
Table 1. To investigate the role of the identiﬁed CCT loci in keratoconus and
POAG, we then tested the implicated CCT loci in disease case-control sets. The
keratoconus datasets comprised cases and controls from Australia (711 keratoco-
nus cases and 2622 controls from the Blue Mountains Eye Study) and the United
States (222 keratoconus cases and 3324 controls). The POAG cases and controls
were drawn from studies in Australia (1155 cases and 1992 controls) and the
United States (3853 cases and 33480 controls). Detailed information of the kera-
toconus and POAG cohorts can be found in the Supplementary Note 1. The local
research and medical ethics committees approved the individual studies. Written
informed consent was obtained from all participants (or parents in case of minors)
in accordance with the Declaration of Helsinki.
Ancestry-speciﬁc and cross-ancestry GWAS meta-analyses. All participating
studies performed association testing under an additive model for the effect of the
risk allele while adjusting for age, sex and at least the ﬁrst ﬁve principle compo-
nents for the population-based studies. In samples with related individuals asso-
ciation testing accounting for family structure was conducted using the –fastAssoc
option in MERLIN53 or the –mmscore54 option implemented in GenABEL55.
Before meta-analysis, we removed variants with MAF < 0.01, and with imputation
quality scores less than 0.3.
Ancestry speciﬁc meta-analyses (European-speciﬁc and Asian-speciﬁc) and
joint meta-analysis were performed using the inverse variance ﬁxed effect scheme
implemented in the software METAL56. The ‘genomic inﬂation’ correction option
was used in METAL56 and applied to all input ﬁles. We also computed the test
statistics for heterogeneity of effect among studies for each variant using Cochran’s
Q-test. We removed variants with heterogeneity P-value < 0.001 from both
European-speciﬁc and Asian-speciﬁc meta-analyses. Moreover, we focused on
variants that were present in more than 25% of participating studies in the
European-speciﬁc meta-analysis (at least four studies) and the Asian-speciﬁc meta-
analysis (at least two studies). Finally, to detect additional loci associated with CCT,
we performed a ﬁxed-effect cross ancestry meta-analysis.
Selecting independent variants. We applied the conditional and joint (CoJo)
analysis approach57 implemented in the software Genome-wide Complex Trait
Analysis58 (GCTA) on European-speciﬁc meta-analysis results in order to identify
potentially independent signals within the same genomic regions. For this CoJo
analysis we used 1000 genomes phase 1 imputed data from Blue Mountain Eye
Study (BMES) population cohort comprising 2582 individuals of European
ancestry to calculate linkage disequilibrium (LD) patterns. We used the software
GTOOL-v0.7.5 (http://www.well.ox.ac.uk/%7Ecfreeman/software/gwas/gtool.html)
to convert BMES IMPUTE2 data (both SNPs and Indels) to the plink format. This
conversion changes A/T/G/C/I/D/R based allele coding to 1 or 2 (ﬁrst and second
allele). We extracted variant IDs, hg19 genomic locations and converted A/T/G/C/
I/D/R (from 1/2 based allele coding) for all 16,666,330 available variants (MAF >
0.01) from BMES data and merged it with the European-speciﬁc meta-analysis
result ﬁle based on hg19 genomic location. Further quality checking was done by
plotting the allele frequencies of the allele 1 of variants in chromosome 22 in the
BMES cohort and European-speciﬁc meta-analysis summary ﬁle. The edited
European-speciﬁc meta-analysis summary ﬁle with 1/2 allele coding was used as an
input for the CoJo analysis. In the CoJo analysis we considered 5 × 10−8 as the
genome-wide signiﬁcant threshold. We did not perform CoJo analysis in the Asian
studies because the various Asian sub-studies (Indian, Malay, Chinese) had
differing ancestry within Asia and we did not have access to a suitably large (i.e., N
> 2000) reference genotype data set for each Asian sub-population.
Gene-based analysis. We performed gene-based association testing using the
VEGAS2 software20. VEGAS2 is an extension of the VErsatile Gene-based Asso-
ciation Study (VEGAS) approach59 that uses 1000 genomes reference data to
estimate LD between variants and provides a test using a more ﬂexible gene
boundary. For this analysis, we considered ‘−10 kbloc’ parameter, which assigns all
variants in the gene or within 10 kb on either side of a gene’s transcription site to
compute a gene-based P-value. We performed analysis using the default ‘-top 100’
test that uses all (100%) variants assigned to a gene to compute gene-based P-value.
We used 1000 Genomes phase 1 European and Asian populations to compute LD
between variants for European-speciﬁc and Asian-speciﬁc gene-based analysis
respectively. Finally, we meta-analysed the European-speciﬁc and Asian-speciﬁc
gene-based results using Fisher’s method for combining P-values.
Analysis of case-control cohorts. We tested the lead CCT-associated SNPs in two
keratoconus datasets with 933 cases and 5946 controls and two POAG datasets
with 5008 cases and 35,472 controls. Details of the disease cohorts can be found in
the Supplementary Note 1. For both keratoconus and POAG we meta-analysed the
association results for individual study samples using a ﬁxed effect approach. The
signiﬁcance threshold for replication was established using the Bonferroni method
for multiple testing correction.
CCT-associated loci and Mendelian diseases. We assessed whether the CCT-
associated loci overlapped with candidate genes for rare Mendelian diseases. For
this analysis we downloaded the most up-to-date annotations of genes to the
Mendelian disease from the Online Mendelian Inheritance in Man (OMIM) por-
tal60 on 26th July 2016. We converted the genomic locations of CCT-associated
variants from hg19 (or GRCh37) to the GRCh38 human genome build using the
software liftOver61,62 and extracted all gene transcription start sites that lie within
the 1 mega-base (Mb) on either side of a given variant.
Identifying regulatory variants. Using the software HaploReg (version 4.1)25 and
RegulomeDB v1.122, we investigated regulatory annotations for variants in LD (r2
> 0.8, 1000 genomes CEU) with the CCT-associated SNPs. To prioritize functional
SNPs, we ﬁrst used HaploRegv4.1 to extract all variants in LD with the 54 inde-
pendent index SNPs and examined whether variants overlapped with regulatory
elements of the ENCODE data, with the caveat that those do not include corneal
tissue or cell lines data. We then used the RegulomeDB score to assess their
potential functional consequence, as described previously63. Tissue-enrichment
and gene prioritization analyses were performed with the DEPICT23 framework,
using independent CCT genome-wide signiﬁcant SNPs. We also investigated the
expression of functionally relevant genes in associated loci using the Ocular Tissue
Database, https://genome.uiowa.edu/otdb/, in which gene expression is indicated as
Affymetrix Probe Logarithmic Intensity Error (PLIER) normalized value (with
normalization in PLIER as described in Wagner et al.,43). Further, we used
GARFIELD to assess enrichment of CCT association signals in regulatory features,
using the 1005 features extracted from ENCODE, GENCODE and Roadmap
Epigenomics projects provided by the software developers.
Pathways analysis based on VEGAS2 gene-based P-values. We adopted the
resampling approach to perform pathway analyses using VEGAS2 derived gene-
based P-values considering a ‘−10 kbloc’ and ‘−200 kbloc’ parameters respectively.
The latter was performed to capture a larger number of nearby genes, in case the
causal SNP or SNPs operate via long distance effects on genes in the wider region.
The resampling approach performs a competitive test in which each gene-set is
benchmarked against the ‘typical’ set of the same size. For individual gene-set,
ﬁrstly we computed observed summed χ2 statistics by converting gene-based P-
values of annotated genes to upper tail χ2 statistics with 1 degree of freedom. If two
or more genes in a gene-set were located less than 500 kb of individual tran-
scription sites, then only one gene was selected when computing the observed
summed χ2 statistics and the other neighbouring genes were dropped out. This step
might lead to loss of information but it ensures that the association of a gene-set is
not driven by variants in LD. Following this, the same numbers of genes as present
in a given gene set were repeatedly drawn at random from all set of genes used in
the study and summed to generate the distribution of expected summed χ2 sta-
tistics. Finally, the empirical P-value of association of a gene-set is computed by
comparing the observed summed χ2 statistics against the distribution of expected
summed χ2 statistics using following formula:
EmpP ¼
PN
1 I χ
2  χ2ð Þ þ 1
Nþ 1
where I() is an indicator function which denotes whether a summed χ2 statistics
from a random draw (χ2*) was equal to or more than the observed summed χ2
statistics (χ2), and N is the total number of random draws performed to compute
the distribution of expected summed χ2 statistics.
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We performed separate European-speciﬁc and Asian-speciﬁc pathway analysis,
and further combined the two ethnic-speciﬁc pathway P-values using the Fisher’s
method. For pathway analysis, we considered the Biosystem’s pathways or gene-
sets comprising minimum 10 and maximum 1000 genes64. In total 9981 gene-sets
with 16,503 unique annotated genes were analysed. The processed Biosystems
pathway/gene-set annotation ﬁle is available on the VEGAS2 webpage (https://vega
s2.qimrberghofer.edu.au/).
Pathway analysis using INRICH. We also tested if single variants with association
P-values less than 1 × 10−4 were enriched in the Biosystem’s pathways. For this
analysis, we used the INRICH approach, which assumes a hypergeometric dis-
tribution for the null hypothesis that a pathway is not enriched with associated
variants. To create LD-independent genomic regions to be tested for enrichment,
we performed LD clumping with PLINK (--clump-p1 1 × 10−4 --clump-p2 0.05
--clump-r2 0.5 --clump-range-border 20), using the 1000 Genomes European and
Asian reference data, for European-speciﬁc and Asian-speciﬁc gene-set enrichment
analyses respectively.
Pathway analysis using Ingenuity Pathway Analysis. To select the genes
included in the IPA®, we extracted the genes +/− 200 kb of the lead SNP and
further chose those that were expressed in the cornea (Supplementary Table 12).
Corneal expression levels were retrieved from the Ocular Tissue Database43. A gene
list including 162 genes was used to run the IPA “Core-Analysis”. Parameters of the
analysis included (1) the Ingenuity Knowledge Base (Genes only) as the reference
set, (2) including direct and indirect relationships, (3) experimentally observed, (4)
from mammal species, (5) using all tissues and cell lines. Results were corrected for
multiple testing using the Benjamini-Hochberg multiple testing correction as
implemented in IPA.
URLs. GARFIELD software is available in a standalone version at http://www.ebi.
ac.uk/birney-srv/GARFIELD/ and as a Bioconductor package at http://
bioconductor.org/packages/release/bioc/html/garﬁeld.html.
Data availability. Summary association statistics results that support the ﬁndings
of this study have been deposited in http://hdl.handle.net/10283/2976.
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